Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis

41Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Interstitial pneumonitis (IP) is a serious complication in polymyositis/dermatomyositis (PM/DM), leading to significant morbidity or mortality. Here, we report the successful treatment by pulse intravenous administration of cyclophosphamide in the early course of lung involvement in PM, and with subsequent low-dosage oral administration of azathioprine in a patient with steroid-resistant IP associated with PM/DM. Although the precise pharmacological mechanism induced by cyclophosphamide in this disease remains unclear, such a cytotoxic drug raises the possibility of control steroid- resistant PM/DM-associated IP when used in the early course of IP.

Cite

CITATION STYLE

APA

Yoshida, T., Koga, H., Saitoh, F., Sakamoto, M., Harada, M., Yoshida, H., … Sata, M. (1999). Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Internal Medicine, 38(9), 733–738. https://doi.org/10.2169/internalmedicine.38.733

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free